The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReckitt Regulatory News (RKT)

Share Price Information for Reckitt (RKT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,379.00
Bid: 4,385.00
Ask: 4,387.00
Change: -33.00 (-0.75%)
Spread: 2.00 (0.046%)
Open: 4,417.00
High: 4,451.00
Low: 4,379.00
Prev. Close: 4,412.00
RKT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EMTN Programme: Publication of Final Terms

14 Sep 2023 14:30

RNS Number : 5001M
Reckitt Benckiser Group PLC
14 September 2023
 

14 September 2023

 

RECKITT BENCKISER GROUP PLC

 

EMTN Programme: Publication of Final Terms

 

Reckitt Benckiser Group plc (the "Company"), together with Reckitt Benckiser Treasury Services plc (the "Issuer"), announce that on 5 September 2023, they successfully launched and priced the following notes under the GBP 10,000,000,000 Euro Medium Term Note Programme of the Issuer and Reckitt Benckiser Treasury Services (Nederland) B.V.:

 

- EUR 650,000,000 3.625% Fixed Rate Senior Notes due 14 September 2028;

- EUR 750,000,000 3.875% Fixed Rate Senior Notes due 14 September 2033; and

- GBP 300,000,000 5.625% Fixed Rate Senior Notes due 14 December 2038,

 

(together the "Notes"), each issued by the Issuer and guaranteed by the Company. The Notes are expected to be issued on 14 September 2023.

 

The Final Terms dated 12 September 2023 relating to the Notes are available for viewing. To view the full documents, please paste the following URL into the address bar of the browser:

 

https://reckitt.com/investors/your-shareholding/emtn-programme-documents/

 

A copy of the Final Terms has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

The Final Terms should be read and construed in conjunction with the Base Prospectus dated 4 September 2023.

 

For further Information:

 

Richard Joyce +44 (0)7807 418516

Investor Relations

 

Catheryn O'Rourke +44 (0) 1753 217 800

Company Secretary

 

About Reckitt:

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege. 

 

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more. 

 

Every day, more than 30 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always. 

 

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com 

 

* Reckitt is the trading name of the Reckitt Benckiser group of companies 

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

 

This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire any securities.

 

The securities referred to herein and the guarantee thereof have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and are subject to Unites States tax law requirements. Subject to certain exceptions, the securities referred to herein may not be offered, sold or delivered in the United States (as defined in Regulation S under the Securities Act) or to, or for the account or benefit of, U.S. persons (as defined in the U.S. Internal Revenue Code of 1986, as amended, and regulations thereunder). The Base Prospectus may not be accessed from, or transmitted in or into, the United States. Accordingly, these securities may not be offered, sold or delivered in the United States.

 

Please note that the information contained in the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Final Terms and the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCNKQBBNBKDBCD
Date   Source Headline
16th Nov 20237:00 amRNSTransaction in Own Shares
15th Nov 20237:00 amRNSChair Succession
15th Nov 20237:00 amRNSTransaction in Own Shares
14th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSTransaction in Own Shares
10th Nov 20237:00 amRNSTransaction in Own Shares
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
7th Nov 20237:00 amRNSTransaction in Own Shares
6th Nov 20237:00 amRNSTransaction in Own Shares
3rd Nov 20237:05 amRNSTransaction in Own Shares
2nd Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202311:57 amRNSTotal Voting Rights
1st Nov 20237:00 amRNSTransaction in Own Shares
31st Oct 20237:00 amRNSTransaction in Own Shares
30th Oct 20237:00 amRNSShare Buyback Programme - First Tranche
27th Oct 20237:00 amRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSStrategy Update
25th Oct 20237:00 amRNSQ3 Trading Statement
2nd Oct 202310:12 amRNSTotal Voting Rights
18th Sep 20234:30 pmRNSDirector/PDMR Shareholding
14th Sep 20232:30 pmRNSEMTN Programme: Publication of Final Terms
5th Sep 20239:35 amRNSPublication of Base Prospectus
1st Sep 202311:16 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSCEO Transition
23rd Aug 20237:00 amRNSDirectorate Change
9th Aug 20233:15 pmRNSDirector/PDMR Shareholding
7th Aug 20234:31 pmRNSDirector/PDMR Shareholding
1st Aug 20239:50 amRNSTotal Voting Rights
27th Jul 20232:06 pmRNSDirector/PDMR Shareholding
26th Jul 20237:00 amRNSHalf-year Report
3rd Jul 202310:58 amRNSTotal Voting Rights
1st Jun 202311:05 amRNSTotal Voting Rights
31st May 202312:15 pmRNSDirector/PDMR Shareholding
25th May 20235:00 pmRNSDirector/PDMR Shareholding
25th May 202312:00 pmRNSSmaller related party transaction
3rd May 20235:22 pmRNSResult of AGM
2nd May 20231:19 pmRNSTotal Voting Rights
26th Apr 20237:00 amRNSNew CEO Announcement
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 202311:20 amRNSTotal Voting Rights
22nd Mar 202311:30 amRNSDirector/PDMR Shareholding
22nd Mar 202310:05 amRNSAnnual Financial Report and Notice of AGM
1st Mar 20235:31 pmRNSCorrection: Last date for DRIP election
1st Mar 20237:01 amRNSTotal Voting Rights
1st Mar 20237:00 amRNSFinal Results
15th Feb 202311:00 amRNSDirector Declaration
1st Feb 202312:51 pmRNSTotal Voting Rights
3rd Jan 202311:19 amRNSTotal Voting Rights
13th Dec 202210:30 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.